Précédent|Prochain

Phlorizin Ameliorates Glucose and Lipid Metabolism Disorders in T2DM Rats by Modulating IRS-1/PI3K/Akt Signaling Pathway

  • role： First author第一作者
  • Affiliation：

    Jiangxi University of Chinese Medicine， Nanchang 330004，China

  • Email：nuerailiaili@163.com
  • Introduction：努尔·艾力，在读硕士，从事中药资源与药效学研究，E-mail：nuerailiaili@163.com
Nuer Aili1,  
  • Affiliation：

    Nanchang Medical College， Nanchang 330052，China

CAO Qingyu2,  
  • Affiliation：

    Jiangxi University of Chinese Medicine， Nanchang 330004，China

LIU Huan1,  
  • Affiliation：

    Jiangxi University of Chinese Medicine， Nanchang 330004，China

HE Junwei1,  
  • role： Corresponding author通信作者
  • Affiliation：

    Jiangxi University of Chinese Medicine， Nanchang 330004，China

  • Email：zhongweihong@jxutcm.edu.cn
  • Introduction：钟卫红，讲师，从事中药和民族药资源与品质评价研究，E-mail：zhongweihong@jxutcm.edu.cn
ZHONG Weihong1*,  
  • role： Corresponding author通信作者
  • Affiliation：

    Jiangxi University of Chinese Medicine， Nanchang 330004，China

  • Email：674179402@qq.com
  • Introduction：曹岚，硕士，副教授，从事中药资源与民族药研究，E-mail：674179402@qq.com； *
CAO Lan1*

résumé

ObjectiveTo observe the pharmacodynamic efficacy of phlorizin in improving hepatic glycolipid metabolism disorders in type 2 diabetic mellitus （T2DM） rats and to explore its mechanism of action based on the insulin receptor substrate-1 （IRS-1）/phosphatidylinositol 3-kinase （PI3K）/protein kinase B （Akt） signaling pathway.MethodsA high-fat diet and streptozotocin （STZ） were used to establish T2DM rat models. The rats were randomly assigned into six groups： the blank control group， model group， metformin group （300 mg·kg-1）， and phlorizin high-dose （100 mg·kg-1） and low-dose groups （25 mg·kg-1）. The rats were given intragastric administration for 6 weeks. The changes in body weight and fasting blood glucose （FBG） were observed， and the oral glucose tolerance test （OGTT） was carried out. The levels of total cholesterol （TC）， triglyceride （TG）， low-density lipoprotein cholesterol （LDL-C）， high-density lipoprotein cholesterol （HDL-C）， glycated serum protein （GSP）， aspartate aminotransferase （AST）， and alanine aminotransferase （ALT） in serum were detected by an automatic biochemical analyzer. The levels of fasting insulin （FINS）， interleukin （IL）-1β， IL-6， and tumour necrosis factor （TNF）-α were detected by enzyme-linked immunosorbent assay （ELISA）. The levels of superoxide dismutase （SOD） and malondialdehyde （MDA） were detected by the biochemical assays. The pancreas index， liver index， and insulin resistance index were calculated. Hematoxylin-eosin （HE） staining was used to evaluate the pathological changes in liver and pancreatic tissues. The immunofluorescence method was used to detect the changes in insulin and glucagon in pancreatic tissue. Western blot was used to detect the expression of related proteins in the IRS-1/PI3K/Akt pathway of liver tissue and its downstream glycogen synthase kinase-3β （GSK-3β） and forkhead box transcription factor O1 （FoxO1） proteins.ResultsCompared with the blank control group， the body weight of rats in the model group continued to decrease， while the FBG level increased significantly. The area under the OGTT blood glucose curve （AUC）， GSP， TC， TG， LDL-C， IL-1β， IL-6， TNF-α， MDA， pancreatic index and liver index increased significantly， while the levels of HDL-C， SOD， and FINS decreased significantly （P0.05， P0.01）. Histological results showed that the pancreatic islets of rats in the model group exhibited atrophy and severe structural abnormalities. The insulin-positive β-cells decreased significantly （P0.01）， while the glucagon-positive α-cells increased significantly （P0.01）. Inflammatory cell infiltration and partial necrosis were observed in the liver tissues of the model group rats. The expressions of p-IRS-1/IRS-1， p-GSK-3β/GSK-3β， and p-FoxO1/FoxO1 proteins in the liver of the model group increased significantly （P0.01）， while the expressions of p-PI3K/PI3K and p-Akt/Akt proteins decreased significantly （P0.01）. Compared with the model group， the diabetic symptoms of rats in all administration groups were improved. The changes in body weight and FBG were close to those of the blank control group. The levels of OGTT-AUC， GSP， TC， TG， LDL-C， MDA， IL-1β， IL-6， TNF-α and the pancreatic index， liver index were obviously reduced （P0.05， P0.01）， while the levels of HDL-C， SOD， and FINS obviously increased （P0.05， P0.01）. The pathological changes of the pancreas and liver in rats in all treatment groups were effectively improved. The insulin-positive β-cells in the pancreas increased significantly （P0.01）， while the glucagon-positive α-cells decreased significantly （P0.01）. The protein expressions of p-IRS-1/IRS-1， p-GSK-3β/GSK-3β， and p-FoxO1/FoxO1 in the liver were significantly reduced （P0.01）， while the protein expressions of p-PI3K/PI3K and p-Akt/Akt significantly increased （P0.01）.ConclusionPhlorizin reversed the weight loss and abnormal increase of FBG in T2DM rats， improved blood lipid profiles， oxidative stress， and inflammatory levels， alleviated insulin resistance， and had certain protective effects on the liver and pancreas. The hypoglycemic mechanism may involve regulating the IRS-1/PI3K/Akt signaling pathway to inhibit the activities of GSK-3β and FoxO1， thereby promoting liver glycogen synthesis and suppressing hepatic gluconeogenesis， ultimately improving glycolipid metabolism disorders.

mots-clés

phlorizin;insulin receptor substrate-1（IRS-1）/phosphatidylinositol 3-kinase （PI3K）/protein kinase B （Akt）;type 2 diabetes mellitus （T2DM）;insulin resistance;glucose and lipid metabolism

References

  1. 1.
    SUN L，ZHOU Y B，ZHANG M G，et al.Association of major chronic noncommunicable diseases and life expectancy in China，2019［J］.Healthcare，2022，10（2）：296.
  2. 2.
    GBD 2021 Diabetes Collaborators.Global，regional，and national burden of diabetes from 1990 to 2021，with projections of prevalence to 2050：A systematic analysis for the Global Burden of Disease Study 2021［J］.Lancet，2023，402（10397）：203-234.
  3. 3.
    LI Y L，CHEN D，XU C M，et al.Glycolipid metabolism and liver transcriptomic analysis of the therapeutic effects of pressed degreased walnut meal extracts on type 2 diabetes mellitus rats［J］.Food Funct，2020，11（6）：5538-5552.
  4. 4.
    GALICIA-GARCIA U，BENITO-VICENTE A，JEBARI S，et al.Pathophysiology of type 2 diabetes mellitus［J］.Int J Mol Sci，2020，21（17）：6275.
  5. 5.
    DUAN Y H，DAI H Y，AN Y C，et al.Total flavonoids of mulberry leaves improves liver lipid metabolism in type 2 diabetic rats by regulating PPAR-α/CPT-1 pathway［J］.Chin J Exp Tradit Med Form，2022，28（15）：61-69.
  6. 6.
    HEEREN J，SCHEJA L.Metabolic-associated fatty liver disease and lipoprotein metabolism［J］.Mol Metab，2021，50：101238.
  7. 7.
    WATT M J，MIOTTO P M，DE NARDO W，et al.The liver as an endocrine organ—linking NAFLD and insulin resistance［J］.Endocr Rev，2019，40（5）：1367-1393.
  8. 8.
    EL-HAFIDI M，FRANCO M，RAMÍREZ A R，et al.Glycine increases insulin sensitivity and glutathione biosynthesis and protects against oxidative stress in a model of sucrose-induced insulin resistance［J］.Oxid Med Cell Longev，2018，2018：2101562.
  9. 9.
    HUANG X J，LIU G H，GUO J，et al.The PI3K/Akt pathway in obesity and type 2 diabetes［J］.Int J Biol Sci，2018，14（11）：1483-1496.
  10. 10.
    ZHANG S X，ZHANG S，ZHANG Y，et al.Activation of Nrf2 by epiberberine improves oxidative stress and insulin resistance in T2DM mice and IR-HepG2 cells in an AMPK dependent manner［J］.J Ethnopharmacol，2024，doi：.
  11. 11.
    LIU F J，CHANG L L，WANG W L，et al.Hepatic insulin resistance and type 2 diabetes mellitus［J］.Acta Acad Med Sin，2022，44（4）：699-708.
  12. 12.
    ELDAR-FINKELMAN H，KREBS E G.Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action［J］.Proc Natl Acad Sci USA，1997，94（18）：9660-9664.
  13. 13.
    FAN X C，JIAO G Y，PANG T，et al.Ameliorative effects of mangiferin derivative TPX on insulin resistance via PI3K/Akt and AMPK signaling pathways in human HepG2 and HL-7702 hepatocytes［J］.Phytomedicine，2023，doi：.
  14. 14.
    ZHANG Y，LI L，CHAI T，et al.Mulberry leaf multi-components exert hypoglycemic effects through regulation of the PI3K/Akt insulin signaling pathway in type 2 diabetic rats［J］.J Ethnopharmacol.2024，319（Pt3）：117307.
  15. 15.
    WANG M K，LIU X，ZHANG Z J，et al.Phytochemicals and bioactive analysis of different sweet tea （Lithocarpus litseifolius Hance Chun） varieties［J］.J Food Biochem，2021，45（3）：e13183.
  16. 16.
    YUAN X，HOU S Z，LAI X P.Progress on the pharmacological effects of phloridzin［J］ J Guangdong Pharm Univ，2015，31（6）：833-836.
  17. 17.
    BLASCHEK W.Natural products as lead compounds for sodium glucose cotransporter （SGLT） inhibitors［J］.Planta Med，2017，83（12/13）：985-993.
  18. 18.
    ZHAO H，ZHAI B W，ZHANG M Y，et al.Phlorizin from Lithocarpus litseifolius［Hance］ Chun ameliorates FFA-induced insulin resistance by regulating AMPK/PI3K/Akt signaling pathway［J］.Phytomedicine，2024，doi：.
  19. 19.
    LI D，YANG Y L，SUN L J，et al.Effect of young apple （Malus domestica Borkh cv. Red Fuji） polyphenols on alleviating insulin resistance［J］.Food Biosci，2020，36：100637.
  20. 20.
    YANG M L，LU C，FAN Z F，et al.Hypoglycemic and hypolipidemic effects of Epigynum auritum in high fat diet and streptozotocin-induced diabetic rats［J］.J Ethnopharmacol，2022，288：114986.
  21. 21.
    ZHANG W，CHEN S Q，FU H L，et al.Hypoglycemic and hypolipidemic activities of phlorizin from Lithocarpus polystachyus Rehd in diabetes rats［J］.Food Sci Nutr，2021，9（4）：1989-1996.
  22. 22.
    Shen L，YOU B A，GAO H Q，et al.Effects of phlorizin on vascular complications in diabetes db/db mice［J］.Chin Med J，2012，125（20）：3692-3696.
  23. 23.
    CHU S Z，ZHANG F，WANG H Y，et al.Aqueous extract of Guava （Psidium guajava L.） leaf ameliorates hyperglycemia by promoting hepatic glycogen synthesis and modulating gut microbiota［J］.Front Pharmacol，2022，13：907702.
  24. 24.
    WEI S，LI J，HAN D W，et al.Regulatory effect of herbal pair Huangqi-Gegen on PI3K/Akt/FoxO1 signaling pathway in rats with T2DM based on network pharmacology［J］.Chin J Exp Tradit Med Form，2022，28（5）：157-168.
  25. 25.
    MA Z Q，GAO J M，KONG H，et al.Research progress of pharmacological effects of phlorizin［J］.Herald Med，2020，39（3）：360-364.
  26. 26.
    ZHOU Q Y，GUAN Z Q，LIU S F，et al.The effects of metformin and alendronate in attenuating bone loss and improving glucose metabolism in diabetes mellitus mice［J］.Aging，2022，14（1），272-285.
  27. 27.
    ZHANG X P，LI C D，et al.Research progress on relationship and mechanism between abnormal lipid metabolism and diabetic kidney disease［J］.World Clin Drugs，2022，43（7）：927-931.
  28. 28.
    LIU Y P，XU Z，HUANG H Y，et al.Fucoidan ameliorates glucose metabolism by the improvement of intestinal barrier and inflammatory damage in type 2 diabetic rats［J］.Int J Biol Macromol，2022，201：616-629.
  29. 29.
    HOOPER P L，BALOGH G，RIVAS E，et al.The importance of the cellular stress response in the pathogenesis and treatment of type 2 diabetes［J］.Cell Stress Chaperones，2014，19（4）：447-464.
  30. 30.
    RUZE R，LIU T T，ZOU X，et al.Obesity and type 2 diabetes mellitus：Connections in epidemiology，pathogenesis，and treatments［J］.Front Endocrinol，2023，14：1161521.
  31. 31.
    DAO L S，CHOI S，FREEBY M.Type 2 diabetes mellitus and cognitive function：Understanding the connections［J］.Curr Opin Endocrinol Diabetes Obes，2023，30（1）：7-13.
  32. 32.
    ZHANG Y L，HAN C S，ZHU W Z，et al.Glucagon potentiates insulin secretion via β-cell gcgr at physiological concentrations of glucose［J］.Cells，2021，10（9）：2495.
  33. 33.
    TITCHENELL P M，LAZAR M A，BIRNBAUM M J.Unraveling the regulation of hepatic metabolism by insulin［J］.Trends Endocrinol Metab，2017，28（7）：497-505.
  34. 34.
    BOURA-HALFON S，ZICK Y.Phosphorylation of IRS proteins，insulin action，and insulin resistance［J］.Am J Physiol Endocrinol Metab，2009，296（4）：E581-E591.
  35. 35.
    LIU X J，CAI S B，YI J J，et al.Chinese sumac fruits （Rhus chinesis Mill.） alleviate type 2 diabetes in C57BL/6 mice through repairing islet cell functions，regulating IRS-1/PI3K/Akt pathways and promoting the entry of Nrf2 into the nucleus［J］.Nutrients，2023，15（18）：4080.
  36. 36.
    YUAN Y L，LIN B Q，ZHANG C F，et al.Timosaponin B-Ⅱ ameliorates palmitate-induced insulin resistance and inflammation via IRS-1/PI3K/Akt and IKK/NF-κB pathways［J］.Am J Chin Med，2016，44（4）：755-769.

Lire l'article complet

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website